These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10363031)

  • 1. The plasminogen activation system in lung cancer--with special reference to the prognostic role in "non-small cell lung cancer".
    Pappot H
    APMIS Suppl; 1999; 92():1-29. PubMed ID: 10363031
    [No Abstract]   [Full Text] [Related]  

  • 2. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
    Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
    Di Bernardo MC; Matakidou A; Eisen T; Houlston RS;
    Lung Cancer; 2009 Aug; 65(2):237-41. PubMed ID: 19117638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.
    Weidle UH; Wöllisch E; Rønne E; Ploug M; Behrendt N; de Vries TJ; Quax PH; Verheijen JH; van Muijen GN; Ruiter DJ
    Ann Biol Clin (Paris); 1994; 52(11):775-82. PubMed ID: 7747886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of markers of possible prognostic value in 57 giant cell tumors of bone.
    Gamberi G; Serra M; Ragazzini P; Magagnoli G; Pazzaglia L; Ponticelli F; Ferrari C; Zanasi M; Bertoni F; Picci P; Benassi MS
    Oncol Rep; 2003; 10(2):351-6. PubMed ID: 12579271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
    Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
    D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
    Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
    Shih CM; Kuo WH; Lin CW; Chen W; Cheng WE; Chen SC; Lee YL
    Clin Chim Acta; 2011 Jan; 412(1-2):194-8. PubMed ID: 20937265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
    Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
    Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
    Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
    Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
    Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activation by receptor-bound urokinase.
    Ellis V; Danø K
    Semin Thromb Hemost; 1991 Jul; 17(3):194-200. PubMed ID: 1665584
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
    Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
    Almasi CE; Høyer-Hansen G; Christensen IJ; Danø K; Pappot H
    Lung Cancer; 2005 Jun; 48(3):349-55. PubMed ID: 15893003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
    Yang SF; Hsieh YS; Lin CL; Hsu NY; Chiou HL; Chou FP; Chu SC
    Clin Chim Acta; 2005 Apr; 354(1-2):91-9. PubMed ID: 15748604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.